Key result
The AdaBoost machine learning model outperformed the CHA2DS2-VASc score in predicting major adverse cardiovascular events in patients with atrial fibrillation (AUC 99.99% vs 81.71%; p=0.0034).
Why the study?
AF is associated with a high risk of MACEs, and this study aimed to compare the predictive ability of an ML model versus the CHA2DS2-VASc score for predicting MACEs in AF patients.
Does an AdaBoost machine learning model improve the prediction of major adverse cardiovascular events compared to the CHA2DS2-VASc score in older patients with atrial fibrillation?
Cohort (n=40,297)
Does an AdaBoost machine learning model improve the prediction of major adverse cardiovascular events compared to the CHA2DS2-VASc score in older patients with atrial fibrillation?
Absolute Event Rate: 99.99% vs 81.71%
p-value: p=0.0034
An AdaBoost machine learning model demonstrated significantly superior predictive performance for major adverse cardiovascular events in older patients with atrial fibrillation compared to the traditional CHA2DS2-VASc score.
ML models may refine MACE prediction in AF beyond CHA2DS2-VASc; leaves open prospective validation before any practice change.
Background/Objectives: Atrial fibrillation (AF) is a prevalent arrhythmia associated with a high risk of major adverse cardiovascular events (MACEs). This study aimed to compare the predictive ability of an ML model and the CHA2DS2-VASc score in predicting MACEs in AF patients using machine learning (ML) techniques. Methods: A cohort of 40,297 individuals aged 65–95 from the Terres de l’Ebre region (Catalonia, Spain) and diagnosed with AF between 2015 and 2016 was analyzed. ML algorithms, particularly AdaBoost, were used to predict MACEs, and the performance of the models was evaluated through metrics such as recall, area under the ROC curve (AUC), and accuracy. Results: The AdaBoost model outperformed CHA2DS2-VASc, achieving an accuracy of 99.99%, precision of 0.9994, recall of 1, and an AUC of 99.99%, compared to CHA2DS2-VASc’s AUC of 81.71%. A statistically significant difference was found using DeLong’s test (p = 0.0034) between the models, indicating the superior performance of the AdaBoost model in predicting MACEs. Conclusions: The AdaBoost model provides significantly better prediction of MACE in AF patients than the CHA2DS2-VASc score, demonstrating the potential of ML algorithms for personalized risk assessment and early detection in clinical settings. Further validation and computational resources are necessary to enable broader implementation.
No takes yet. Share an insight, caveat, or question.
Moltó-Balado et al. (2025) conducted a cohort in Atrial fibrillation (n=40,297). AdaBoost machine learning model vs. CHA2DS2-VASc score was evaluated on Major adverse cardiovascular events (MACEs) (p=0.0034). The AdaBoost machine learning model outperformed the CHA2DS2-VASc score in predicting major adverse cardiovascular events in patients with atrial fibrillation (AUC 99.99% vs 81.71%; p=0.0034).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: